Results 41 to 50 of about 747,551 (253)

Establishing an Apheresis Medicine Program in a Resource‐Constrained Setting: A 5‐Year Experience From Lagos, Nigeria

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Rasheed A. Balogun   +4 more
wiley   +1 more source

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial [PDF]

, 2013
Background: Neo-tAnGo, a National Cancer Research Network (NCRN) multicentre randomised neoadjuvant chemotherapy trial in early breast cancer, enroled 831 patients in the United Kingdom.
K Walland, N Fenwick, M Iddawela, E Provenzano, Walland, K., Abraham, J. (Janet), Grier, Anna, L Hiller, J Abraham, A Grier, Fenwick, Nicola, Bowden, S. (Sarah), Iddawela, M., Caldas, C., H M Earl, R Champ, S Bowden, J Dunn, Vallier, A. -L., Champ, R., Earl, Helena M., C Caldas, Dunn, Janet A., Hiller, Louise, A-L Vallier, Provenzano, E.   +25 more
core   +2 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Preoperative SCC-Ag as a predictive marker for the use of adjuvant chemotherapy in cervical squamous cell carcinoma with intermediate-risk factors

BMC Cancer, 2020
Background For cervical cancer patients whose tumors display a combination of intermediate risk factors, postoperative radiation with or without adjuvant chemotherapy is suggested for them.
Hong-tao Guo, Xue-han Bi, Ting Lei, Xiao Lv, Guang Yao, Yao Chen, Chang Liu   +6 more
doaj   +1 more source

The impact of Oncotype DX testing on adjuvant chemotherapy decision making in 1–3 node positive breast cancer

Cancer Reports, 2022
Background Oncotype DX testing has reduced the use of adjuvant chemotherapy in node‐negative early breast cancer but less is known about its impact in node positive patients.
Yogeshkumar Malam, Mohamed Rabie, Konstantinos Geropantas, Susanna Alexander, Simon Pain, Mina Youssef   +5 more
doaj   +1 more source

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study [PDF]

, 2008
Summary Myelosuppression, particularly febrile neutropenia (FN), are serious dose-limiting toxicities that occur frequently during the first cycle of chemotherapy.
Impact of Neutropenia in Chemotherapy-European Study Group (INC-, Paridaens, R, Szucs, Thomas D., Matthias Schwenkglenks, Pettengell, R, Bosly, André, Schwenkglenks, Matthias, Jackisch, C, Jackisch, Christian, Thomas D. Szucs, Manuel Constenla, Constenla, Manuel, Szucs, T D, Schwenkglenks, M, André Bosly, Leonard, Robert, Paridaens, Robert, Christian Jackisch, Robert Leonard, Pettengell, Ruth, Ruth Pettengell, Robert Paridaens, Bosly, A, Impact of Neutropenia in Chemotherapy-European Study Group,, Szucs, TD, Leonard, R, Constenla, M   +26 more
core   +1 more source

An isoform of 14‐3‐3 protein regulates transbilayer lipid movement at the plasma membrane

FEBS Letters, EarlyView.
Loss of 14‐3‐3ζ in CHO cells confers resistance to exogenous phosphatidylserine (PS) and impairs endocytosis‐independent inward flip‐flop of fluorescent PS at the plasma membrane. RNAi‐mediated knockdown reproduces this defect, while no additive effect is seen in ATP11C‐deficient cells.
Akiko Yamaji‐Hasegawa, Akira Hattori, Masafumi Tsujimoto, Toshihide Kobayashi   +3 more
wiley   +1 more source

Chemotherapy effects on brain glucose metabolism at rest [PDF]

, 2011
Background: A growing number of studies reports that chemotherapy may impair brain functions inducing cognitive changes which can persist in a subset of cancer survivors.
Riccardo Torta, Elisabetta Geda, Bruno Baudino, Katiuscia Sacco, Gianni Bisi, Federico D'Agata, Giancarlo Castellano, Laura Orsi, Simona Cauda, Rita Ardito, Lorys Castelli, Matteo Manfredi, Paola Caroppo, Antonella Parente, Franco Cauda   +14 more
core  

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy : systematic review and meta-analysis [PDF]

, 2011
Background: Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays.
Akehurst Ron L, Cooper, K. (Katy), Ph. D., Whyte, Sophie, Whyte Sophie, Akehurst, R.L., Madan, Jason, Akehurst, Ron L., Madan, J., Whyte, S., Madan Jason, Katy L Cooper, Cooper, K.L., Jason Madan, Ron L Akehurst, Stevenson Matt D, Sophie Whyte, Stevenson, M. (Matt), Cooper Katy L, Stevenson, M.D., Matt D Stevenson   +19 more
core   +2 more sources

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source